Research
Metabolic adaptation
SGLT2 inhibitors are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia.
Practitioners can consider SGLT2 inhibitors as a treatment option for managing blood pressure and weight in T2DM patients.
StrongSupportsmedium confidence
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of oral glucose-lowering agents, are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia.
Why this rating
Based on clinical trial results discussed in the abstract.
Source
Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Helmut O. Steinberg · Postgraduate Medicine · 2016
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →